A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Feb 2008 The expected completion date for this trial is now 1 Sep 2007.
- 14 Nov 2007 Status changed from recruiting to completed.